An analysis of bone regeneration at a segmental bone defect by controlled release of bone morphogenetic protein 2 from a biodegradable sponge composed of gelatin and β-tricalcium phosphate
- 27 June 2011
- journal article
- research article
- Published by Hindawi Limited in Journal of Tissue Engineering and Regenerative Medicine
- Vol. 6 (4), 291-298
- https://doi.org/10.1002/term.432
Abstract
To treat large bone defects is a clinically challenging problem and utilizing tissue engineering technology is an attractive approach for overcoming such a problem. Previously, a biodegradable sponge incorporating bone morphogenic protein‐2 (BMP‐2), which can control the release of BMP‐2 for a prolonged time in an in vivo environment, was reported. In addition, a biodegradable sponge composed of gelatin and β‐tricalcium phosphate (βTCP), gelatin‐βTCP sponge to develop a more ideal scaffold for enhancing bone regeneration was also created and previously reported. The purpose of this study was to investigate the effectiveness of the gelatin‐βTCP sponge for the promotion of bone regeneration in a critical‐sized bone defect site in vivo. Apparent bone regeneration was induced by the gelatin sponge incorporating BMP‐2 and the gelatin‐βTCP sponge with BMP‐2 incorporation. In contrast, no apparent bone formation was induced by either the gelatin sponge only or the gelatin‐βTCP sponge without BMP‐2. To investigate the quality of the regenerated bone, we conducted a biomechanical evaluation with a three‐point bending test. We found no significant difference between the gelatin sponge incorporating BMP‐2 and the gelatin‐βTCP sponge incorporating BMP‐2 groups. Incorporation of βTCP into the gelatin sponge was expected to enhance biomechanical strength during the initial bone regeneration. However, our observations showed that the gelatin‐βTCP sponge did not significantly improve the quality of regenerated bone from the viewpoint of biomechanical assessment, even though it did not impair the effectiveness of the promotion of bone regeneration by BMP‐2 in the bone defect. Copyright © 2011 John Wiley & Sons, Ltd.Keywords
This publication has 19 references indexed in Scilit:
- A local application of recombinant human fibroblast growth factor 2 for tibial shaft fractures: A randomized, placebo-controlled trialJournal of Bone and Mineral Research, 2010
- An injectable composite material containing bone morphogenetic protein‐2 shortens the period of distraction osteogenesis in vivoJournal of Orthopaedic Research, 2010
- Retention of in vitro and in vivo BMP-2 bioactivities in sustained delivery vehicles for bone tissue engineeringBiomaterials, 2008
- Repair of long intercalated rib defects in dogs using recombinant human bone morphogenetic protein‐2 delivered by a synthetic polymer and beta‐tricalcium phosphateJournal of Biomedical Materials Research Part A, 2008
- Bone regeneration using a naturally grown HA/TCP carrier loaded with rh BMP-2 is independent of barrier-membrane effectsJournal of Biomedical Materials Research Part A, 2007
- Enhanced osteoinduction by controlled release of bone morphogenetic protein-2 from biodegradable sponge composed of gelatin and β-tricalcium phosphateBiomaterials, 2005
- Initiation of Fracture Repair by Bone Morphogenetic ProteinsClinical Orthopaedics and Related Research, 1998
- Use of an Osteoinductive Biomaterial (rhOP-1) in Healing Large Segmental Bone DefectsJournal of Orthopaedic Trauma, 1998
- Recombinant human bone morphogenetic protein-2 and collagen for bone regenerationJournal of Biomedical Materials Research, 1998
- Indomethacin and Aspirin: Effect of Nonsteroidal Anti-Inflammatory Agents on the Rate of Fracture Repair in the RatActa Orthopaedica, 1980